Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 49,416 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 49,416 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were bought at an average cost of $7.85 per share, with a total value of $387,915.60. Following the purchase, the director directly owned 5,230,578 shares in the company, valued at approximately $41,060,037.30. This trade represents a 0.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc purchased 22,700 shares of Electra Therapeutics stock. The stock was bought at an average cost of $8.45 per share, for a total transaction of $191,815.00.
• On Monday, November 9th, Orbimed Advisors Llc purchased 20,000 shares of Electra Therapeutics stock. The stock was bought at an average cost of $8.24 per share, for a total transaction of $164,800.00.
• On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The shares were purchased at an average price of $7.31 per share, with a total value of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The stock was purchased at an average price of $15.00 per share, for a total transaction of $19,999,995.00.

Electra Therapeutics Stock Performance

NASDAQ ETRA traded down $0.23 on Tuesday, reaching $7.99. The stock had a trading volume of 298,185 shares, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Analyst Ratings Changes

ETRA has been the subject of several recent research reports. HC Wainwright began coverage on Electra Therapeutics in a research note on Monday, October 26th. They issued a “buy” rating and a $30.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective on the stock. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Cantor Fitzgerald initiated coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “overweight” rating for the company. Finally, Evercore assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.